FDA proof-of-concept trials with AstraZeneca and Amgen validate continuous data transmission and signal detection, setting ...
In today's ACT Brief, we recap key themes from DIA 2026 on operational priorities and regulatory shifts, examine ...
In today's ACT Brief, we examine integrating site and sponsor data systems, a high-profile trial retraction over integrity concerns, and a new first-line breast cancer treatment. This is the Applied ...
In this Q&A, Raj Indupuri, CEO and co-founder of eClinical Solutions, discusses what the FDA's push toward continuous data review actually demands of sponsors operationally, why fragmented systems are ...
Clinical trial sponsors are navigating a shifting landscape that includes both long-established life sciences companies ...
In this video interview following the 2026 DIA Global Annual Meeting, Jonathan Andrus, co-CEO of CRIO, explains why ...
In today's ACT Brief, we examine regulatory uncertainty and 2026 breakthroughs shaping clinical research, reimagining CRO ...
Beyond Revenue Recognition: Rethinking CRO Contracting Through the CURED Shared Performance Contract
This article argues that improving financial outcomes—including more reliable revenue recognition—requires revisiting the ...
Traditional CRO contracting models create misalignment between effort, progress, and financial outcomes, driving revenue recognition risk and margin volatility, but shared performance contracts ...
In today's ACT Brief, we examine HHS coordinated effort to restore US clinical research leadership, two decades of rising ...
Insilico Medicine and SK Biopharmaceuticals entered an R&D collaboration on AI-enabled drug discovery in neuroimmune CNS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results